McKinsey’s 2030 vision: A challenge for medical affairs 2 days ago McKinsey’s vision for Medical Affairs in 2030 envisions profound integration of digital tools, analytical innovation, evidence generation, and leade
Why is your medicine so expensive? 5 days ago Bringing a drug to market is a costly and intricate process, averaging $2.3 billion. This expense encompasses multiple levels of testing, ranging from
Dan Sfera Podcast 8 days ago #pharma #pharmaceuticals Website: http://www.darshantalks.com Law Firm: http://www.kulkarnilawfirm.com Twitter: https://twitter.com/darshantalks Link
3 must-do takeaways for collecting diversity data in clinical trials 9 days ago In an ideal world, every patient in clinical trials would feel truly represented. In this video, Darshan Kulkarni outlines three crucial takeaways for
Who's REALLY Responsible for a Clinical Trial Congruency review? 16 days ago In this short, we discuss who is responsible for a congruency review in clinical trials. Our guest Istvan Fekete emphasizes that both pharmaceutical c
Key elements of a successful congruency review for clinical trial agreements 1 months ago In a congruency review, the primary objective is to ensure alignment across various elements in clinical research. The initial crucial step involves a
McKinsey’s 2030 vision: A challenge for medical affairs 2 days ago McKinsey’s vision for Medical Affairs in 2030 envisions profound integration of digital tools, analytical innovation, evidence generation, and leade
Medical Affairs Strategic Thinking & Changing Landscape | Darshan Talks 11 months ago In this episode of the DarshanTalks Podcast, host Darshan Kulkarni Pharm.D, MS, Esq. welcomes Biopharma Medical Affairs expert, Irene von Hennigs, Pha
Little-known Facts about Non Therapeutic Uses of Drugs and Devices | Patti Zettler In today’s episode of DarshanTalks Podcast, host Darshan Kulkarni welcomes guest Patti Zettler to talk about the non-therapeutic uses of drugs and d